This multicenter randomized trial is designed to assess the efficacy of lipid-lowering therapy in patients undergoing percutaneous coronary intervention, comparing an Apolipoprotein B-targeted approach with a Low-Density Lipoprotein Cholesterol (LDL-C)-targeted approach. The primary outcomes are to evaluate the proportion of patients achieving lipid-lowering treatment goals at the 1-year follow-up between the two treatment strategies: Apolipoprotein B-based therapy versus LDL-C-based therapy.
Patients aged 18 years or older.
Patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES).
Patients who agree to participate and provide informed consent.
Inability to Provide Informed Consent: Patients who are unable or unwilling to provide consent.
Limited life expectancy: patients with a life expectancy of less than 12 months due to other non-cardiac conditions.
Liver Disease: patients with cirrhosis or significant liver dysfunction.
Patients with contraindication to statin or other lipid-lowering therapy.
University Medical Center Ho Chi Minh City (UMC)
Lead sponsor
University of Medicine and Pharmacy at Ho Chi Minh City
Sponsor institution
University of Medicine and Pharmacy at Ho Chi Minh City
Collaborator